NewLimit raises $130 million in Series B funding to combat aging using AI and genomics, led by Kleiner Perkins and supported by notable investors.
NewLimit raises $130 million in Series B funding to combat aging using AI and genomics, led by Kleiner Perkins and supported by notable investors.
05/07/25, 4:41 AM
Location
south san franciscoMoney raised
$130 million
Industry
biotechnology
Round Type
series b
Investors
Khosla Ventures, Daniel Gross, Nat Friedman, Patrick Collison, Garry Tan, Elad Gil, Dimension Capital, Founders Fund, Kleiner Perkins
NewLimit, a biotech startup co-founded by Coinbase CEO Brian Armstrong, has secured $130 million in a Series B round. This funding aims to enhance their development of therapies to slow aging through AI-driven cell reprogramming. The total funding for NewLimit now exceeds $170 million. Notable investors include Kleiner Perkins, Founders Fund, and Khosla Ventures.
Company Info
Location
south san francisco, california, united states
Additional Info
NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.